IL146934A0 - Use of antibodies afainst cd20 for the treatment of the graft versus host disease - Google Patents

Use of antibodies afainst cd20 for the treatment of the graft versus host disease

Info

Publication number
IL146934A0
IL146934A0 IL14693400A IL14693400A IL146934A0 IL 146934 A0 IL146934 A0 IL 146934A0 IL 14693400 A IL14693400 A IL 14693400A IL 14693400 A IL14693400 A IL 14693400A IL 146934 A0 IL146934 A0 IL 146934A0
Authority
IL
Israel
Prior art keywords
afainst
antibodies
treatment
host disease
versus host
Prior art date
Application number
IL14693400A
Other languages
English (en)
Original Assignee
Consiglio Naz Delle Richerche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consiglio Naz Delle Richerche filed Critical Consiglio Naz Delle Richerche
Publication of IL146934A0 publication Critical patent/IL146934A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL14693400A 1999-06-11 2000-06-07 Use of antibodies afainst cd20 for the treatment of the graft versus host disease IL146934A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1999MI001299A ITMI991299A1 (it) 1999-06-11 1999-06-11 Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite
PCT/EP2000/005212 WO2000076542A1 (fr) 1999-06-11 2000-06-07 Utilisation d'anticorps contre cd20 pour traiter la maladie de rejet du greffon

Publications (1)

Publication Number Publication Date
IL146934A0 true IL146934A0 (en) 2002-08-14

Family

ID=11383150

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14693400A IL146934A0 (en) 1999-06-11 2000-06-07 Use of antibodies afainst cd20 for the treatment of the graft versus host disease

Country Status (26)

Country Link
US (1) US20070014785A1 (fr)
EP (1) EP1185299B1 (fr)
JP (1) JP2003501482A (fr)
KR (1) KR20020026455A (fr)
CN (1) CN1253208C (fr)
AU (1) AU774206B2 (fr)
BG (1) BG106193A (fr)
CA (1) CA2376288A1 (fr)
CZ (1) CZ20014450A3 (fr)
DE (1) DE60033030T2 (fr)
DK (1) DK1185299T3 (fr)
EE (1) EE200100667A (fr)
ES (1) ES2278616T3 (fr)
HK (1) HK1043549B (fr)
HU (1) HUP0201600A3 (fr)
IL (1) IL146934A0 (fr)
IS (1) IS6195A (fr)
IT (1) ITMI991299A1 (fr)
NO (1) NO20016035L (fr)
NZ (1) NZ515992A (fr)
PL (1) PL352860A1 (fr)
PT (1) PT1185299E (fr)
SK (1) SK18132001A3 (fr)
TR (1) TR200103581T2 (fr)
WO (1) WO2000076542A1 (fr)
ZA (1) ZA200110004B (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2372603C (fr) 1999-05-07 2015-11-17 Genentech, Inc. Traitement de maladies auto-immunes au moyen d'antagonistes se liant aux marqueurs de surface de lymphocytes b
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
KR20070055625A (ko) * 2002-12-16 2007-05-30 제넨테크, 인크. 이뮤노글로불린 변이체 및 이들의 용도
CN1316019C (zh) * 2002-12-26 2007-05-16 中国医学科学院中国协和医科大学血液学研究所血液病医院 抗cd20嵌合抗体突变体基因及其应用
RU2358762C9 (ru) 2003-04-09 2016-10-10 Джинентех, Инк. Лечение аутоиммунных заболеваний у пациента с неадекватным ответом на ингибитор tnf-альфа
JP5416338B2 (ja) 2003-05-09 2014-02-12 デューク ユニバーシティ Ｃｄ２０特異的抗体およびその使用方法
DK1631313T3 (en) 2003-06-05 2015-06-15 Genentech Inc Combination therapy for b cell disorders
CA2560751A1 (fr) * 2004-03-22 2005-10-06 The Ohio State University Research Foundation Methodes permettant de transfecter des cellules k naturelles
KR20150092374A (ko) 2004-06-04 2015-08-12 제넨테크, 인크. 다발성 경화증의 치료 방법
BR122018016031B8 (pt) 2004-08-04 2021-07-27 Applied Molecular Evolution Inc processo para produzir um anticorpo monoclonal variante com resposta de adcc realçada
AU2006251647A1 (en) 2005-05-20 2006-11-30 Genentech, Inc. Pretreatment of a biological sample from an autoimmune disease subject
BRPI0614183A2 (pt) 2005-07-25 2011-03-15 Trubion Pharmaceuticals Inc uso de dose única de moléculas de ligação especìficas para cd20
CN105012953B (zh) 2005-07-25 2018-06-22 阿普泰沃研发有限责任公司 用cd37-特异性和cd20-特异性结合分子减少b-细胞
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
ES2618543T3 (es) 2005-11-23 2017-06-21 Genentech, Inc. Métodos y composiciones relacionados con ensayos de linfocitos B
CN101008291B (zh) * 2006-01-26 2010-05-12 金海产品有限公司 用于水池清洁机的密封盒装置
RU2487888C2 (ru) 2006-06-12 2013-07-20 ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ, ЭлЭлСи Одноцепочечные мультивалентные связывающие белки с эффекторной функцией
CA2584494A1 (fr) * 2007-03-27 2008-09-27 Jeffrey A. Medin Vecteur codant un polypeptide therapeutique et elements de securite permettant de verifier les cellules transduites
EP2163896B1 (fr) * 2007-06-22 2013-09-25 Sapporo Medical University Procédé de détection ou de traitement de la maladie du greffon contre l'hôte
KR20190140090A (ko) 2007-07-09 2019-12-18 제넨테크, 인크. 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
WO2009018411A1 (fr) 2007-07-31 2009-02-05 Regeneron Pharmaceuticals, Inc. Anticorps humains en cd20 humain et leur procédé d'utilisation
EP2233149B1 (fr) 2007-10-16 2016-02-10 ZymoGenetics, Inc. Combinaison de l'activateur transmembranaire et modulateur calcique et interacteur du ligand de cyclophiline (TACI) et d'un agent anti-CD20 pour le traitement des maladies auto-immunes
EP2077281A1 (fr) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anticorps anti-CD20 ou fragments correspondants pour le traitement de syndrome de fatigue chronique
WO2009114942A1 (fr) 2008-03-20 2009-09-24 University Health Network Fusions de thymidylate kinase et leurs utilisations
ATE513856T1 (de) 2008-04-11 2011-07-15 Emergent Product Dev Seattle Cd37-immuntherapeutikum und kombination mit bifunktionellem chemotherapeutikum davon
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
WO2010075249A2 (fr) 2008-12-22 2010-07-01 Genentech, Inc. Méthode de traitement de la polyarthrite rhumatoïde avec des antagonistes de cellules b
KR20200111282A (ko) 2009-08-11 2020-09-28 제넨테크, 인크. 글루타민-비함유 세포 배양 배지에서의 단백질의 생성
MX341687B (es) 2010-02-10 2016-08-30 Immunogen Inc "anticuerpos cd20 y su utilización".
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
SI3221359T1 (sl) 2014-11-17 2020-08-31 Regeneron Pharmaceuticals, Inc. Metode zravljenja tumorja z uporabo bispecifičnega protitelesa CD3XCD20
KR102647100B1 (ko) 2015-05-30 2024-03-13 몰레큘러 템플레이츠, 인코퍼레이션. 탈면역된 시가 독소 a 서브유닛 스캐폴드 및 이를 포함하는 세포-표적화 분자
CN113999312A (zh) 2015-06-24 2022-02-01 豪夫迈·罗氏有限公司 具有定制亲和力的抗转铁蛋白受体抗体
CA2999138C (fr) 2015-09-21 2024-05-21 Aptevo Research And Development Llc Polypeptides de liaison a cd3
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
PE20181004A1 (es) 2015-10-02 2018-06-26 Hoffmann La Roche Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso
AU2017370942A1 (en) 2016-12-07 2019-06-13 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
EP3600416B1 (fr) 2017-03-30 2023-06-07 Biora Therapeutics, Inc. Traitement d'une maladie du tractus gastro-intestinal avec un agent immunomodulateur libéré à l'aide d'un dispositif ingérable
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246317A1 (fr) 2018-06-20 2019-12-26 Progenity, Inc. Traitement d'une maladie ou d'un état dans un tissu provenant de l'endoderme
WO2020047389A1 (fr) 2018-08-31 2020-03-05 Regeneron Pharmaceuticals, Inc. Stratégie de dosage permettant d'atténuer le syndrome de libération de cytokines pour des anticorps bispécifiques cd3/c20
EP3883635A1 (fr) 2018-11-19 2021-09-29 Progenity, Inc. Méthodes et dispositifs pour traiter une maladie au moyen d'une biothérapie
US11707610B2 (en) 2019-12-13 2023-07-25 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272082A (en) * 1992-03-30 1993-12-21 The Wistar Institute Of Anatomy & Biology Cytotoxic T-ALL cell lines and uses therefor
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
JP2000511539A (ja) * 1996-05-31 2000-09-05 ジェネティック・セラピー・インコーポレイテッド 負の選択マーカーをコード化するポリヌクレオチドを含むｔ細胞による対宿主性移植片病の予防
GB9705744D0 (en) * 1997-03-20 1997-05-07 Davies Alison M Methods for selecting cells and their uses

Also Published As

Publication number Publication date
AU774206B2 (en) 2004-06-17
DK1185299T3 (da) 2007-05-21
EP1185299B1 (fr) 2007-01-17
BG106193A (bg) 2002-08-30
SK18132001A3 (sk) 2002-05-09
WO2000076542A1 (fr) 2000-12-21
KR20020026455A (ko) 2002-04-10
NO20016035D0 (no) 2001-12-10
DE60033030D1 (de) 2007-03-08
ITMI991299A1 (it) 2000-12-11
US20070014785A1 (en) 2007-01-18
CA2376288A1 (fr) 2000-12-21
ITMI991299A0 (it) 1999-06-11
PT1185299E (pt) 2007-03-30
CZ20014450A3 (cs) 2002-04-17
HUP0201600A3 (en) 2005-04-28
DE60033030T2 (de) 2007-05-31
HK1043549B (zh) 2006-09-01
AU5530300A (en) 2001-01-02
NZ515992A (en) 2004-01-30
IS6195A (is) 2001-12-10
EE200100667A (et) 2003-02-17
ES2278616T3 (es) 2007-08-16
NO20016035L (no) 2002-02-11
JP2003501482A (ja) 2003-01-14
CN1253208C (zh) 2006-04-26
ZA200110004B (en) 2003-02-26
CN1355712A (zh) 2002-06-26
HK1043549A1 (en) 2002-09-20
EP1185299A1 (fr) 2002-03-13
HUP0201600A2 (en) 2002-08-28
PL352860A1 (en) 2003-09-08
TR200103581T2 (tr) 2002-08-21

Similar Documents

Publication Publication Date Title
IL146934A0 (en) Use of antibodies afainst cd20 for the treatment of the graft versus host disease
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
EP1355563A4 (fr) Procedes de prevention et de traitement du cancer au moyen d'anticorps anti-c3b(i)
IL160884A0 (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
AU2002239491A1 (en) Methods for the treatment of cancer and other diseases and methods of developing the same
IL160998A0 (en) Human tissue factor antibodies
EP1178829A4 (fr) Anticorps monoclonal humain
HUP0400775A2 (en) Specific human antibodies for selective cancer therapy
AU8322401A (en) Indole compounds useful for the treatment of cancer
MXPA02004942A (es) Nuevo uso de anticuerpos como vacunas.
HK1051692A1 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain.
AU2001243349A1 (en) Methods for the diagnosis and treatment of breast cancer
IL155237A0 (en) Combination therapy for the treatment of estrogen-sensitive disease
ZA200110539B (en) Oxazinocarbazoles for the treatment of CNS diseases.
SI1185299T1 (sl) Uporaba protiteles proti cd20 za zdravljenje reakcije presadka proti gostitelju
HRP20020262A2 (en) Substituted pyrroles as antiproliferative agents for the treatment of cancer
ZA200203166B (en) Treatment of cancer.
AU2002364774A1 (en) Ilk inhibitors for the treatment of renal disease
AU6896300A (en) Vaccines for the treatment of autoimmune disease
SI1157041T1 (sl) Protitelesa za terapijo in diagnozo raka
GB9828564D0 (en) Materials and methods for the treatment and diagnosis of cancer
GB9914057D0 (en) Antibody therapy
GB9927698D0 (en) Therapeutic antibody
IL131335A0 (en) Emulsions for cancer treatment
ZA200308844B (en) Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease.